LOS ANGELES--(BUSINESS WIRE)--Clinical studies using Bruin Biometrics’ OrthoSonos device show promising trends in the detection of early stage osteoarthritis (OA) that could lead to better treatments. OrthoSonos is being revealed to a select group of physicians at an invite-only event during AAOS on March 13th.
“The data is highly encouraging and points to the possibility of a new, evidence-based patient assessment tool being available to Rheumatologists and Orthopedic Surgeons in the near future,” said Martin Burns, CEO of Bruin Biometrics. “Early detection of minor and mild-stage OA offers an exciting chance to manage the disease.”
Initial data show that patients with confirmed severe OA who are scheduled for arthroplasty demonstrate a consistently negative OrthoSonos Health Index (OHI), while patients with healthy joints have a consistently positive OHI. Patients with OA for whom surgery is not yet required reported OHIs trending from healthy to chronic joints.
About Bruin Biometrics
Bruin Biometrics (BBI) is relentlessly committed to using technology to improve the way that health care is delivered. By developing innovative biometric medical device systems that can cost-effectively detect and monitor select medical conditions with urgent clinical need, BBI is helping inform clinical decisions, simplify patient care, and improve patient outcomes. BBI has developed the SEM Scanner, a revolutionary wound care diagnostic medical device to detect the inflammatory changes associated with pressure induced tissue damage. BBI’s second product, the OrthoSonos is an innovative medical device to diagnose and spot monitor the health of joints and prosthetic implants. Neither SEM Scanner nor OrthoSonos are approved for sale by the FDA. The SEM scanner has been CE Mark approved in the EU and is currently in full commercial launch. OrthoSonos is on track for commercial launch in Q4, 2014. To learn more about BBI please visit www.bruinbiometrics.com.